FDA accepts file and accelerates review of Novartis sickle cell disease medicine crizanlizumab (SEG101)

FDA accepts file and accelerates review of Novartis sickle cell disease medicine crizanlizumab (SEG101)

Jul 16, 2019
Source URL: https://qa1.novartis.us/news/media-releases/fda-accepts-file-and-accelerates-review-novartis-sickle-cell-disease-medicine-crizanlizumab-seg101-0

List of links present in page
  1. https://qa1.novartis.us/news/media-releases/fda-accepts-file-and-accelerates-review-novartis-sickle-cell-disease-medicine-crizanlizumab-seg101-0